1. Home
  2. YSG vs IMRX Comparison

YSG vs IMRX Comparison

Compare YSG & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$3.11

Market Cap

288.0M

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$4.12

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
IMRX
Founded
2016
2008
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.0M
340.7M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
YSG
IMRX
Price
$3.11
$4.12
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$17.20
AVG Volume (30 Days)
243.9K
2.2M
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.08
N/A
Revenue Next Year
$9.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$1.67
52 Week High
$11.04
$10.08

Technical Indicators

Market Signals
Indicator
YSG
IMRX
Relative Strength Index (RSI) 52.83 39.57
Support Level $2.76 N/A
Resistance Level $3.23 $5.47
Average True Range (ATR) 0.39 0.55
MACD 0.02 -0.09
Stochastic Oscillator 51.34 9.57

Price Performance

Historical Comparison
YSG
IMRX

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: